(Columbia University Medical Center) Researchers at the Columbia University College of Dental Medicine have identified a genetic variation that raises the risk of developing serious necrotic jaw bone lesions in patients who take bisphosphonates, a common class of osteoclastic inhibitors. The discovery paves the way for a genetic screening test to determine who can safely take these drugs.

Last Reviewed 02/Mar/2014

Related Posts

The following two tabs change content below.



Latest posts by Editor (see all)